glp 1 with kidney disease Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria GLP1 Receptor Agonists vs SGLT2-I

Pflipsen & Vega Colon (2020)

While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimers disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk, said in a statement

Momentum is already strong in these areas, but integrating their combined strengths to enhance targeting, optimise efficacy and reduce adverse effects all in the form of a convenient tablet it really might be a case of the sky being the limit

Moreover, GLP-1 injections undergo rigorous FDA testing and require medical supervision , ensuring safety and efficacy that patches, sold as supplements, cannot match